The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Losing weight can feel like climbing a mountain with no clear path. The one-size-fits-all advice—like “eat less, move ...

Weight-loss drugs have been rolled out by the NHS, but many are buying them through social media and online pharmacies ...

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

GLP-1s currently used for weight loss—although not all are expressly approved for this purpose—include Ozempic and Wegovy ...

The Study will compare an oral version of liraglutide, formulated from the DehydraTECH-processing of Saxenda® ("DehydraTECH ... most widely used GLP-1 drugs; semaglutide (Novo Nordisk®) and ...

The Study will compare an oral version of liraglutide, formulated from the DehydraTECH-processing of Saxenda® ("DehydraTECH-liraglutide") to the conventional injected liraglutide (Saxenda®).